News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Change in the number of shares and votes in Egetis Therapeutics

October 31, 2024

Stockholm, Sweden, October 31, 2024. The number of shares and votes in Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (STO: EGTX) has increased in the month of October as a result of the directed issuances of a total of 66,666,667 ordinary shares as announced on September 30, 2024.
The total number of shares and votes has increased by 66,666,667, from 292,571,459 to 359,238,126. The share capital has increased by approximately SEK 3,508,773.256328, from approximately SEK 15,398,503.586561 to approximately SEK 18,907,276.842889.

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]